A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

Completed · Phase 4 · Has a placebo group

Conditions studied: Conjunctivitis, Allergic

In brief

This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.

Key facts

Study ID

NCT01732757

Run by

Allergan

People needed

157

Starts

2012-11-01

Expected to finish

2012-12-01

Last updated by the study team

2014-01-14

Who can join

Age: 10 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• History of ocular allergies within the past 24 months.
• Able to avoid wearing contact lenses for at least 72 hours prior to and during the study trial period.

You may not qualify if…

• Any presence of active ocular infection or history of an ocular herpetic infection.
• Ocular surgery within 3 months prior to the first visit or refractive surgery within the past 6 months.
• Have any planned surgery during the study or 30 days after the study.

Where it is running

• Study site — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.